loading...| Preferred Name |
nivolumab |
|
| Synonyms |
BMS-936558 |
|
| Definitions |
A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1,) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. This results in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and and plays a key role in in tumor evasion from host immunity. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C68814" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C68814" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000539733 |
|
| altLabel |
BMS-936558 Opdivo MDX-1106 anti-PD-1 human monoclonal antibody MDX-1106 Opdivo Injection ONO-4538 NIVO |
|
| cui |
C4552119 C4732986 C3872108 C2346820 C4552118 C3657270 |
|
| DATE FIRST PUBLISHED |
2007-03-22 |
|
| Date last modified |
2016-02-22 |
|
| definition |
A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1,) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. This results in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and and plays a key role in in tumor evasion from host immunity. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C68814" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C68814" NCI Thesaurus) |
|
| LT |
TRD |
|
| NCI ID |
C68814 |
|
| notation |
CDR0000539733 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
nivolumab |
|
| tui |
T116 T129 T121 |